ProtocolsHealing & recoveryWolverine Starter
← Protocols

Wolverine Starter

Stack: BPC-157 + TB-500 · half dose
"The lighter, first-time version of the most-used healing stack on earth. Same honest ceiling as the full version: enormous uptake, no human trial of the combination."
GoalSoft-tissue recovery
Compounds2 · BPC-157 + TB-500
Humans exposed (est.)Very high — undocumented
StatusMHRA (UK): not licensed medicines — research material · FDA (US): status evolving (see below) · no human trials of the combination
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Where / who
Community / athlete and clinic use as tagged above.
Use status
The default first healing stack.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing disrupted legitimate compounding — see the regulatory layer for current status.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Animal / mechanistic only.
Basis required for a clinical-use tag: none found — absence shown, not hidden
FDA (US)
BPC-157 / TB-500 were FDA Category 2 (compounding prohibited) 2023–Apr 2026; removed Apr 2026, under PCAC review (23–24 Jul 2026).
MHRA (UK)
Not licensed medicines. Sold as research material.
What it means
Removal from Category 2 is not approval — the compounding decision is pending.
Why it matters
No marketing authorisation = no pharmacovigilance; adverse events aren't formally tracked.
Basis: FDA Docket FDA-2025-N-6895 · PCAC 23–24 Jul 2026 — updates after the decision
Why this combination

A reduced-dose introduction to the BPC-157 + TB-500 pairing. The mechanistic rationale is the same as the full stack — and so is the evidence gap: preclinical only, no human trial of the combination.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription. Specific timing is part of membership.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.